McCullough PA, et al. – This post hoc pooled analysis examined the efficacy and safety of ferric citrate (FC) in patients with nondialysis–dependent (NDD) chronic kidney disease (CKD) with and without heart failure (HF). Findings demonstrated that irrespective of having HF or not, patients with NDD–CKD and iron deficiency anemia (IDA) exhibited a similar increase in hemoglobin [Hgb] and iron parameters and a decrease in serum phosphate as a consequence of treatment with FC. Additionally, no new safety signals were observed in patients with versus without HF.